2014
DOI: 10.1097/mbc.0000000000000130
|View full text |Cite
|
Sign up to set email alerts
|

Predictors of thrombus burden and no-reflow of infarct-related artery in patients with ST-segment elevation myocardial infarction

Abstract: Preprocedural high-thrombus burden (HTB) of infarct-related artery (IRA) is a harbinger of procedural complications following primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI). The HTB of IRA can lead to poor outcomes by various mechanisms, including no-reflow phenomenon, increased myocardial necrosis and with subsequent reduced survival benefit at follow-up. In this study, we investigated the relationship between all platelet indices on admission and … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
14
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(16 citation statements)
references
References 24 publications
2
14
0
Order By: Relevance
“…However, we did not find any significant difference in MPV value depending on these angiographic findings. This result was similar to a recent report conducted in patients with ST-elevation myocardial infarction, which showed that the MPV was comparable between patients with high-thrombus burden and those with a low-thrombus burden [8]. These results suggested that the MPV was not directly related with ongoing thrombus burden, though a high MPV has been shown to predict future thromboembolic events.…”
Section: To the Editorsupporting
confidence: 93%
“…However, we did not find any significant difference in MPV value depending on these angiographic findings. This result was similar to a recent report conducted in patients with ST-elevation myocardial infarction, which showed that the MPV was comparable between patients with high-thrombus burden and those with a low-thrombus burden [8]. These results suggested that the MPV was not directly related with ongoing thrombus burden, though a high MPV has been shown to predict future thromboembolic events.…”
Section: To the Editorsupporting
confidence: 93%
“…A higher MPV has been associated with more extensive myocardial necrosis and subsequent heart failure [1], increased incidence of myocardial no-reflow, as well as mortality [2] in patients presenting with STEMI. Platelet-large cell ratio (P-LCR) and platelet distribution width (PDW) have also been associated with impaired reperfusion in patients with STEMI [3,4]. In recent years, platelet-to-lymphocyte ratio (PLT/LYM) and platelet-to neutrophil ratio (PLT/NEU) have been investigated as predictors of no-reflow in STEMI [5].…”
Section: Introductionmentioning
confidence: 99%
“…An elevated MPV correlates with poor clinical outcomes among survivors of MI in the era of thrombolysis, and an impaired response to thrombolysis in those with ST segment elevation myocardial infarction (STEMI) [28,55]. MPV is also a strong independent predictor of impaired angiographic reperfusion, in-hospital major adverse cardiovascular events, and 30-day, 6-month, 12-month, and 2-year mortality from STEMI treated via primary PCI [26,30-33,36-38,56]. In addition, a higher MPV on admission is independently associated with impaired microvascular perfusion, a poor postintervention myocardial blush grade, decreased post-PCI thrombolysis, and a poorer myocardial infarction flow grade (thrombolysis in myocardial infarction [TIMI]) in STEMI patients treated via primary PCI [33-36,57].…”
Section: Evidence That Mpv Is a Biomarker Of The Risk And Prognosis Omentioning
confidence: 99%
“…It was suggested that monitoring of MPV after PCI might aid risk stratification. MPV cutoffs for predicting poor clinical outcomes in patients with unselected coronary artery disease treated via PCI are 8.00 to 9.25 fL (Table 1) [11,14,16,26,30,31,33,36-38,43-48,56,60,61]. …”
Section: Evidence That Mpv Is a Biomarker Of The Risk And Prognosis Omentioning
confidence: 99%